However, in the current survey, despite the fact that around 22% of patients with suspected CIDP treated with IVIg were non-responders, over half (54.3%) of these IVIg-NR patients did not undergo TTR testing. The gene discussed is TTR; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.